Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Fenebrutinib"

3 News Found

Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression
Clinical Trials | September 04, 2024

Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression

New Phase II data show vast majority of patients experiencing no relapses or disability progression

Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Clinical Trials | November 14, 2025

Roche reports breakthrough phase III results for investigational multiple sclerosis drug

Fenebrutinib targets cells in the immune system known as B cells and microglia

Multiple sclerosis market to generate sales of $29.8 billion by 2030, forecasts GlobalData
News | April 19, 2023

Multiple sclerosis market to generate sales of $29.8 billion by 2030, forecasts GlobalData

Several late-stage pipeline products have the potential to address some of these unmet needs

Latest Stories

Pfizer completes up to $10 billion acquisition of Metsera

Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg

Lupin achieves S&P Global ESG score of 91

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Dr. Umesh N Jindal Director, Jindal IVF
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India

Packaging